Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-03-23
2000-06-27
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514543, A61K 3135, A61K 31235
Patent
active
060807784
ABSTRACT:
Blood cholesterol levels are correlated with production of amyloid .beta. protein (A.beta.), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A.beta., thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A.beta.. For example, individuals with Apo E4 and high cholesterol, defined as a blood cholesterol level of greater than 200 mg/dl, post menopausal women with high cholesterol levels--especially those who are not taking estrogen, or individuals which high blood cholesterol levels who are not obese are all at risk of developing AD if blood cholesterol levels are not decreased.
REFERENCES:
The Merck Index, Eleventh Edition, Merck & Co., Inc., Rahway, N.J., #5460 and #2374. 1989.
CA 124:250221, Procopiou et al., 1996.
Busciglio et al., "Generation of .beta.-amyloid in the secretory pathway in neuronal and nonneuronal cells," Proc. Nat. Acad. Sci. 90, 2092-2096 (1993).
Farrer et al., "Assessment of Genetic Risk for Alzheimer's Disease among First-Degree relatives," Ann. Neurol. 25: 485-492 (1989).
Goate et al., (1991) "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," Nature 349, 704-706).
Mann and Esiri, "The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's Syndrome," J. Neurol. Sci. 89, 169-179 (1984).
McKhahn et al. "Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work Group* under th4 auspices of Department of Health and Human Services Task Force on Alzheimer's Disease," Neurology 34:939-944 (1984).
Reiman, et al. "Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the .epsilon.4 Allele for Apoliprotein E," N.E.J.Med. 334, 752-758 (1996).
Selkoe, D.J. "Alzeheimer's Disease: Genotypes, Phenotype, and Treatments," Science 275, 630-631 (1997)).
Sparks, D.L. "Intraneuronal .beta.-Amyloid Immunoreactivity in the CNS," Neurobiology of Aging. 17, 291-299 (1996).
Strittmatter et al., "Apoliprotein E: High-avidity binding to .beta.-amyloid and increases frequency of type 4 allel in late-onset familial Alzheimer disease," Proc. Natl. Acad. Sci. U.S.A. 90:1977-1981 (1993).
van Duijn et al. "Familial Aggregation of Alzheimer's Disease and Related Disorder's: A Collaborative Re-Analysis of Case-Control Studies," Int. J. Epidemiol. 20 (suppl 2), S13-S20 (1991).
Yankner, "Mechanisms of Neuronal Degeneration in Alzheimer's Disease," Neuron 16, 921-932. (1996).
Frears, et al., "The role of cholesterol in the biosynthesis of beta-amyloid," Neuroreport. 10(8):1699-705 (1999).
Jarvik, et al., "Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study," Neurology. 45(6):1092-6 (1995).
Wisniewski, et al., "Is Alzheimer's disease an apolipoprotein E amyloidosis?" Lancet. 345(8955):956-8 (1995).
Brown, et al., "A receptor-mediated pathway for cholesterol homeostasis," Science. 232(4746):34-47 (1986).
Nadeau Philip
Yankner Bruce A.
Children's Medical Center Corporation
Jordan Kimberly
LandOfFree
Methods for decreasing beta amyloid protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for decreasing beta amyloid protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for decreasing beta amyloid protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1785156